Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 3
2004 1
2005 2
2006 2
2007 2
2008 5
2009 7
2010 1
2011 5
2012 10
2013 5
2014 5
2015 2
2016 13
2017 8
2018 9
2019 12
2020 14
2021 8
2022 4
2023 8
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Results by year

Filters applied: . Clear all
Page 1
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
Kimball AB, Jemec GBE, Alavi A, Reguiai Z, Gottlieb AB, Bechara FG, Paul C, Giamarellos Bourboulis EJ, Villani AP, Schwinn A, Ruëff F, Pillay Ramaya L, Reich A, Lobo I, Sinclair R, Passeron T, Martorell A, Mendes-Bastos P, Kokolakis G, Becherel PA, Wozniak MB, Martinez AL, Wei X, Uhlmann L, Passera A, Keefe D, Martin R, Field C, Chen L, Vandemeulebroecke M, Ravichandran S, Muscianisi E. Kimball AB, et al. Among authors: reguiai z. Lancet. 2023 Mar 4;401(10378):747-761. doi: 10.1016/S0140-6736(23)00022-3. Epub 2023 Feb 3. Lancet. 2023. PMID: 36746171 Clinical Trial.
Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.
Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, Armstrong AW, Kerdel F, Gold MH, Forman SB, Korman NJ, Giamarellos-Bourboulis EJ, Crowley JJ, Lynde C, Reguiai Z, Prens EP, Alwawi E, Mostafa NM, Pinsky B, Sundaram M, Gu Y, Carlson DM, Jemec GB. Kimball AB, et al. Among authors: reguiai z. N Engl J Med. 2016 Aug 4;375(5):422-34. doi: 10.1056/NEJMoa1504370. N Engl J Med. 2016. PMID: 27518661 Free article. Clinical Trial.
Combining Omalizumab with Another Biotherapy.
Fougerousse AC, Becherel PA, Pallure V, Boyé T, Reguiai Z, Gabison G, Barthelemy H, Badaoui A, Mahé E, Livideanu CB; GEM ResoPso. Fougerousse AC, et al. Among authors: reguiai z. Acta Derm Venereol. 2019 Apr 1;99(4):448-449. doi: 10.2340/00015555-3140. Acta Derm Venereol. 2019. PMID: 30723874 Free article. No abstract available.
Janus kinase inhibitors for the treatment of atopic dermatitis: Real-life data on efficacy and safety in light of the Pharmacovigilance Risk Assessment Committee recommended measures.
Reguiai Z, Becherel PA, Fougerousse AC, Chaby G, Perrot JL, Begon E, Jacobzone-Lévêque C, Boulard C, Badaoui A, Poreaux C, David L, Quiles-Tsimaratos N, Lons-Danic D, Fite C, Liegeon AL, Patchinsky A, Parier J, Garcia C, Estève E, Mohty R, Mery-Bossard L, Maccari F. Reguiai Z, et al. J Eur Acad Dermatol Venereol. 2023 Nov;37(11):e1307-e1309. doi: 10.1111/jdv.19302. Epub 2023 Jul 14. J Eur Acad Dermatol Venereol. 2023. PMID: 37415328 No abstract available.
Impact of Baricitinib on Patients' Quality of Life after One Year of Treatment for Atopic Dermatitis in Real-World Practice: Results of the Observatory of Chronic Inflammatory Skin Diseases Registry.
Reguiai Z, Becherel PA, Perrot JL, Fougerousse AC, Begon E, Poreaux C, Boulard C, Chaby G, Fite C, Zaraa I, Lons-Danic D, Liegeon AL, Parier J, Quiles-Tsimaratos N, David L, Maccari F. Reguiai Z, et al. Acta Derm Venereol. 2023 Oct 6;103:adv14153. doi: 10.2340/actadv.v103.14153. Acta Derm Venereol. 2023. PMID: 37800349 Free PMC article.
Association between hidradenitis suppurativa and spondyloarthritis.
Fauconier M, Reguiai Z, Barbe C, Colosio A, Eschard JP, Salmon JH, Direz G. Fauconier M, et al. Among authors: reguiai z. Joint Bone Spine. 2018 Oct;85(5):593-597. doi: 10.1016/j.jbspin.2017.09.005. Epub 2017 Sep 28. Joint Bone Spine. 2018. PMID: 28965938
Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: protocol of a multinational, phase IV, 1-cohort prospective observational study (the POSITIVE study).
Augustin M, Sommer R, Daudén E, Laws P, de Jong E, Fabbrocini G, Naldi L, Navarini A, Lambert J, Reguiai Z, Gerdes S, Massana E, Obis T, Kasujee I, Mrowietz U. Augustin M, et al. Among authors: reguiai z. BMJ Open. 2023 Feb 15;13(2):e060536. doi: 10.1136/bmjopen-2021-060536. BMJ Open. 2023. PMID: 36792337 Free PMC article.
[Drug induced linear IgA bullous dermatosis].
Montagnac R, Reguiaï Z, Méhaut S, Bressieux JM, Schillinger F. Montagnac R, et al. Among authors: reguiai z. Nephrologie. 2003;24(6):287-92. Nephrologie. 2003. PMID: 14584295 Review. French.
[[Acne: what is the role of the diet]?].
Clape A, Loget J, Reguiai Z. Clape A, et al. Among authors: reguiai z. Rev Prat. 2017 Mar 20;67(3):299-302. Rev Prat. 2017. PMID: 30657296 French. No abstract available.
103 results